# Shandong New Time Pharmaceutical

Source: https://onco.cc/companies/shandong-new-time-pharmaceutical/  
OnCo record `shandong-new-time-pharmaceutical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shandong New Time Pharmaceutical is a Chinese developer in Shandong that sponsors 3 registered cancer trials of F182112 and F182112 single-agent.

## Summary

Shandong New Time Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 2, 2/3, 3), testing F182112, F182112 single-agent, Pomalidomide in relapsed or refractory multiple myeloma, relapsed or refractory multiple myeloma (rrmm), cancer of unknown primary site. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Shandong New Time Pharmaceutical Co., LTD
- Tags: ctgov-sponsor; china; registry-only
- HQ: Shandong, China
- Type: biotech

## Sources

- ClinicalTrials.gov: trials sponsored by Shandong New Time Pharmaceutical: https://clinicaltrials.gov/search?spons=Shandong%20New%20Time%20Pharmaceutical

## Connected records

- trials: [A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07579234/), [A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)](https://onco.cc/trials/nct07761429/), [A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07312188/)

---
JSON: https://onco.cc/api/v1/entities/shandong-new-time-pharmaceutical.json